General MedicationsTOPICALGeneric
TAZAROTENE
TAZAROTENE
Standard Dose
0.045%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview TAZAROTENE is listed in Drugs@FDA under application 215393 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient TAZAROTENE Form and strength LOTION;TOPICAL - 0.045% Sponsor PADAGIS ISRAEL Submission history Latest submission status date: 2025-07-29 00:00:00.
Structured Monograph
Clinical summary
Approval overview TAZAROTENE is listed in Drugs@FDA under application 215393 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TAZAROTENE Form and strength LOTION;TOPICAL - 0.045% Sponsor PADAGIS ISRAEL Submission history Latest submission status date: 2025-07-29 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.